Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for shares of Equillium in a research report issued to clients and investors on Friday, March 28th. Leerink Partnrs analyst T.

Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Immatics in a ...

Leerink lowered the firm’s price target on AirSculpt Technologies (AIRS) to $2.50 from $6.50 and keeps a Market Perform rating on the shares.

Leerink Partners analyst Puneet Souda maintained a Hold rating on Hologic (HOLX – Research Report) on March 28. The company’s shares opened ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

A struggle that pits regional environmental activists against an airport expansion for private jets has national—and even ...

I think we'll get started. Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno ...

On Tuesday, 11 March 2025, MacroGenics (NASDAQ: MGNX) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its robust pipeline of cancer therapeutics and strategic ...

But the deal amount still came 41% below Leerink Partners’ $487 million valuation for 2seventy based on the biotech’s expected future cash flows. Before ending its coverage of 2seventy at the ...

Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here ...